|Videos|October 7, 2022
Translating Evidence to Clinical Practice to Improve Outcomes in Patients with Small Cell Lung Cancer
In a recent OncLive® Scientific Interchange moderated by David R. Gandara, MD, experts discussed the prevalence and pathobiology of SCLC cases in their practices; the role of surgery, radiation, prophylactic cranial irradiation (PCI), and systemic therapy in LS-SCLC; and optimal systemic approaches for ES-SCLC in the first-line and relapsed settings.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5
































